Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Reviva Pharmaceuticals Holdings ( (RVPH) ) has shared an announcement.
On March 18, 2026, Reviva Pharmaceuticals Holdings, Inc. entered into agreements with institutional investors for a registered public offering of common stock, pre-funded warrants and Series G and H warrants, structured at a public offering price of $1.50 per share-and-warrant unit for gross proceeds of $10 million and expected net proceeds of about $9 million. The deal, expected to close around March 20, 2026, will modestly dilute existing shareholders but strengthens Reviva’s balance sheet to fund research and development, including its planned RECOVER-2 Phase 3 trial of brilaroxazine in schizophrenia, while placing short-term limits on additional equity issuance and variable-rate financings that may help stabilize its capital-raising profile.
The most recent analyst rating on (RVPH) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on Reviva Pharmaceuticals Holdings stock, see the RVPH Stock Forecast page.
Spark’s Take on RVPH Stock
According to Spark, TipRanks’ AI Analyst, RVPH is a Neutral.
The score is driven primarily by weak financial fundamentals (no revenue, sizable losses, and ongoing cash burn with reliance on future funding). Technicals also reflect a downtrend with negative momentum. Corporate events add material near-term risk (Nasdaq compliance/delisting pressure and extended regulatory timeline requiring additional financing).
To see Spark’s full report on RVPH stock, click here.
More about Reviva Pharmaceuticals Holdings
Reviva Pharmaceuticals Holdings, Inc. is a late-stage biopharmaceutical company focused on discovering, developing and commercializing next-generation therapeutics for diseases with significant unmet medical needs. Its pipeline targets central nervous system, inflammatory and cardiometabolic disorders and currently includes two in-house discovered drug candidates, brilaroxazine (RP5063) and RP1208, both protected by composition of matter patents in the U.S., Europe and other markets.
Average Trading Volume: 265,280
Technical Sentiment Signal: Sell
Current Market Cap: $10.76M
See more insights into RVPH stock on TipRanks’ Stock Analysis page.